Gain Therapeutics (GANX) Financials

Gain Therapeutics logo
$1.05 -0.06 (-5.41%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$1.11 +0.06 (+5.62%)
As of 11/19/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Gain Therapeutics

Annual Income Statements for Gain Therapeutics

This table shows Gain Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-3.58 -14 -18 -22 -20 -20
Consolidated Net Income / (Loss)
-3.58 -14 -18 -22 -20 -20
Net Income / (Loss) Continuing Operations
-3.58 -14 -18 -22 -20 -20
Total Pre-Tax Income
-3.57 -14 -17 -22 -20 -19
Total Operating Income
-3.48 -14 -18 -22 -20 -19
Total Gross Profit
0.03 0.16 0.14 0.06 0.00 0.00
Total Revenue
0.03 0.16 0.14 0.06 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
3.51 14 18 22 20 19
Selling, General & Admin Expense
1.25 6.83 9.54 11 9.56 8.50
Research & Development Expense
2.26 7.16 8.38 12 11 10
Total Other Income / (Expense), net
-0.09 -0.06 0.28 0.06 0.48 -0.59
Interest & Investment Income
- - - 0.49 0.36 0.24
Other Income / (Expense), net
-0.10 -0.07 -0.10 -0.43 0.12 -0.83
Income Tax Expense
0.01 0.00 0.09 0.08 0.54 0.86
Basic Earnings per Share
($1.33) ($1.37) ($1.48) ($1.71) ($0.89) ($0.61)
Weighted Average Basic Shares Outstanding
2.68M 10.17M 11.88M 13.01M 22.88M 32.97M
Diluted Earnings per Share
($1.33) ($1.37) ($1.48) ($1.71) ($0.89) ($0.61)
Weighted Average Diluted Shares Outstanding
2.68M 10.17M 11.88M 13.01M 22.88M 32.97M
Weighted Average Basic & Diluted Shares Outstanding
- 11.88M 11.88M 16.22M 27.79M 42.24M

Quarterly Income Statements for Gain Therapeutics

This table shows Gain Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 4.79 - - - 3.20
Net Income / (Loss) Attributable to Common Shareholders
-4.01 -8.14 -4.49 -3.77 -4.53 -5.81 -5.28 -4.54 -5.61 -4.68 -3.16
Consolidated Net Income / (Loss)
-4.01 -8.14 -4.49 -3.77 -4.53 -5.81 -5.28 -4.54 -5.61 -4.68 -3.16
Net Income / (Loss) Continuing Operations
-4.01 -8.14 -4.49 -3.77 -4.53 -5.81 -5.28 -4.54 -5.61 -4.68 -3.16
Total Pre-Tax Income
-3.99 -8.14 -4.47 -3.26 -4.43 -5.67 -4.74 -4.47 -5.43 -4.57 -3.09
Total Operating Income
-4.38 -8.18 -4.46 -3.33 -4.37 -5.09 -4.79 -4.47 -5.35 -4.68 -3.20
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
4.38 8.18 4.46 3.33 4.37 5.09 4.79 4.47 5.35 4.68 3.20
Selling, General & Admin Expense
1.87 3.75 1.84 2.11 2.11 2.33 1.94 2.12 2.59 2.54 1.78
Research & Development Expense
2.51 4.44 2.62 1.22 2.26 2.76 2.85 2.35 2.76 2.14 1.42
Total Other Income / (Expense), net
0.38 0.04 -0.02 0.07 -0.06 -0.58 0.05 -0.00 -0.07 0.11 0.12
Interest & Investment Income
0.12 0.08 0.11 0.05 0.04 0.04 0.08 0.08 0.09 0.06 0.04
Other Income / (Expense), net
0.27 -0.04 -0.12 0.02 -0.10 -0.62 -0.03 -0.08 -0.17 0.05 0.07
Income Tax Expense
0.02 0.00 0.01 0.50 0.10 0.14 0.55 0.07 0.18 0.10 0.07
Basic Earnings per Share
($0.22) ($0.42) ($0.17) ($0.08) ($0.16) ($0.19) ($0.15) ($0.11) ($0.13) ($0.11) ($0.07)
Weighted Average Basic Shares Outstanding
17.98M 19.22M 26.53M 22.88M 28.69M 30.34M 35.00M 32.97M 42.23M 42.88M 43.77M
Diluted Earnings per Share
($0.22) ($0.42) ($0.17) ($0.08) ($0.16) ($0.19) ($0.15) ($0.11) ($0.13) ($0.11) ($0.07)
Weighted Average Diluted Shares Outstanding
17.98M 19.22M 26.53M 22.88M 28.69M 30.34M 35.00M 32.97M 42.23M 42.88M 43.77M
Weighted Average Basic & Diluted Shares Outstanding
18.05M 25.54M 26.53M 27.79M 29.56M 35.95M 36.10M 42.24M 42.65M 43.64M 44.53M

Annual Cash Flow Statements for Gain Therapeutics

This table details how cash moves in and out of Gain Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
7.19 29 -30 4.49 -1.41 10
Net Cash From Operating Activities
-3.24 -12 -15 -19 -19 -18
Net Cash From Continuing Operating Activities
-3.24 -12 -15 -19 -19 -18
Net Income / (Loss) Continuing Operations
-3.58 -14 -18 -22 -20 -20
Consolidated Net Income / (Loss)
-3.58 -14 -18 -22 -20 -20
Depreciation Expense
0.01 0.02 0.06 0.08 0.08 0.09
Non-Cash Adjustments To Reconcile Net Income
0.07 1.84 1.32 2.88 2.53 2.61
Changes in Operating Assets and Liabilities, net
0.26 -0.31 1.45 0.44 -1.08 -1.01
Net Cash From Investing Activities
-0.02 -0.09 -15 10 4.98 0.00
Net Cash From Continuing Investing Activities
-0.02 -0.09 -15 10 4.98 0.00
Purchase of Property, Plant & Equipment
-0.02 -0.09 -0.12 -0.02 -0.02 0.00
Sale and/or Maturity of Investments
- 0.00 3.08 12 5.00 0.00
Net Cash From Financing Activities
10 42 -0.08 13 13 28
Net Cash From Continuing Financing Activities
10 42 -0.08 13 13 28
Repayment of Debt
0.00 -0.02 -0.08 -0.09 -0.09 -0.10
Repurchase of Common Equity
-0.47 -0.85 - 0.00 -0.28 -0.40
Issuance of Debt
0.74 - 0.00 9.19 10 7.41
Issuance of Common Equity
0.00 43 0.00 3.54 2.95 18
Other Financing Activities, net
0.00 0.01 - 0.00 0.17 3.47
Effect of Exchange Rate Changes
-0.04 0.10 -0.02 0.49 -0.53 0.47
Cash Income Taxes Paid
- 0.00 0.00 0.13 0.09 0.05

Quarterly Cash Flow Statements for Gain Therapeutics

This table details how cash moves in and out of Gain Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-1.16 6.30 -4.88 -1.67 -1.31 -2.37 2.11 12 -4.30 -3.46 -1.39
Net Cash From Operating Activities
-3.59 -5.76 -6.08 -3.45 -3.82 -5.10 -4.93 -4.62 -4.73 -4.68 -3.05
Net Cash From Continuing Operating Activities
-3.59 -5.76 -6.08 -3.45 -3.82 -5.10 -4.93 -4.62 -4.73 -4.68 -3.05
Net Income / (Loss) Continuing Operations
-4.01 -8.14 -4.49 -3.77 -4.53 -5.81 -5.28 -4.54 -5.61 -4.68 -3.16
Consolidated Net Income / (Loss)
-4.01 -8.14 -4.49 -3.77 -4.53 -5.81 -5.28 -4.54 -5.61 -4.68 -3.16
Depreciation Expense
0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.02 0.03 0.02
Non-Cash Adjustments To Reconcile Net Income
-0.04 1.29 0.28 1.01 0.53 1.15 0.44 0.52 0.63 0.67 0.32
Changes in Operating Assets and Liabilities, net
0.45 1.08 -1.89 -0.71 0.16 -0.46 -0.10 -0.63 0.23 -0.70 -0.22
Net Cash From Financing Activities
-0.15 10 0.81 2.31 2.40 2.47 7.03 17 0.40 1.37 1.75
Net Cash From Continuing Financing Activities
-0.15 10 0.81 2.31 2.40 2.47 7.03 17 0.40 1.37 1.75
Repayment of Debt
-0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.03 -0.03 -0.03 -0.02
Issuance of Common Equity
0.00 - 0.62 2.34 2.42 2.49 - 13 0.43 1.39 1.78
Effect of Exchange Rate Changes
-0.44 0.01 0.38 -0.48 0.11 0.26 0.01 0.10 0.02 -0.14 -0.09

Annual Balance Sheets for Gain Therapeutics

This table presents Gain Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
9.60 39 24 19 12 23
Total Current Assets
8.99 38 21 18 12 22
Cash & Equivalents
7.49 37 7.31 12 10 21
Prepaid Expenses
0.20 0.73 0.85 0.74 0.95 1.22
Plant, Property, & Equipment, net
0.03 0.11 0.14 0.13 0.10 0.07
Total Noncurrent Assets
0.59 1.16 2.86 0.70 0.42 0.51
Intangible Assets
- 0.20 0.21 0.19 0.13 0.10
Other Noncurrent Operating Assets
0.59 0.95 0.71 0.51 0.28 0.40
Total Liabilities & Shareholders' Equity
9.60 39 24 19 12 23
Total Liabilities
3.40 4.17 5.22 6.03 4.78 4.25
Total Current Liabilities
2.11 2.55 4.13 4.95 3.91 3.35
Short-Term Debt
0.02 0.10 0.11 0.12 0.11 0.10
Accounts Payable
0.96 0.56 1.63 1.32 0.95 0.83
Other Current Liabilities
0.89 1.62 2.34 2.39 2.60 2.43
Total Noncurrent Liabilities
1.29 1.61 1.09 1.08 0.87 0.90
Long-Term Debt
0.72 0.59 0.50 0.45 0.33 0.30
Noncurrent Employee Benefit Liabilities
0.17 0.33 0.16 0.31 0.44 0.39
Other Noncurrent Operating Liabilities
0.40 0.70 0.44 0.23 0.05 0.21
Total Equity & Noncontrolling Interests
6.20 35 19 13 7.34 19
Total Preferred & Common Equity
6.20 35 19 13 7.34 19
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
6.20 35 19 13 7.34 19
Common Stock
13 56 57 73 89 119
Retained Earnings
-3.46 -7.03 -21 -39 -61 -101
Accumulated Other Comprehensive Income / (Loss)
-0.15 -0.09 0.04 0.25 -0.25 0.78

Quarterly Balance Sheets for Gain Therapeutics

This table presents Gain Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
14 15 19 14 12 9.83 11 19 15 13
Total Current Assets
13 14 19 14 11 9.31 11 18 15 13
Cash & Equivalents
4.27 11 17 12 9.07 6.69 8.81 17 13 12
Prepaid Expenses
0.91 0.95 1.29 1.32 1.83 2.29 1.44 1.45 1.68 0.92
Plant, Property, & Equipment, net
0.13 0.11 0.12 0.12 0.10 0.10 0.09 0.05 0.05 0.04
Total Noncurrent Assets
0.73 0.60 0.53 0.50 0.38 0.43 0.37 0.46 0.41 0.49
Intangible Assets
0.19 0.17 0.16 0.16 0.13 0.13 0.11 0.09 0.08 0.07
Other Noncurrent Operating Assets
0.54 0.43 0.38 0.35 0.25 0.30 0.25 0.37 0.33 0.43
Total Liabilities & Shareholders' Equity
14 15 19 14 12 9.83 11 19 15 13
Total Liabilities
6.77 5.94 7.41 5.46 5.84 6.14 5.06 4.73 4.13 3.08
Total Current Liabilities
5.76 5.00 6.52 4.59 5.03 5.20 4.17 3.89 3.43 2.37
Short-Term Debt
0.11 0.11 0.11 0.12 0.11 0.13 0.13 0.10 0.12 0.12
Accounts Payable
1.38 1.41 2.05 1.10 2.15 2.71 1.58 1.52 1.22 0.60
Other Current Liabilities
2.92 2.57 3.66 2.67 2.55 2.34 2.46 2.27 2.09 1.65
Total Noncurrent Liabilities
1.00 0.93 0.89 0.86 0.82 0.94 0.89 0.84 0.70 0.71
Long-Term Debt
0.43 0.40 0.38 0.38 0.31 0.33 0.30 0.27 0.22 0.19
Noncurrent Employee Benefit Liabilities
0.16 0.29 0.30 0.32 0.47 0.52 0.53 0.39 0.32 0.31
Other Noncurrent Operating Liabilities
0.26 0.18 0.13 0.10 0.03 0.09 0.07 0.18 0.16 0.22
Total Equity & Noncontrolling Interests
7.33 8.64 12 8.91 5.78 3.70 5.91 14 11 10
Total Preferred & Common Equity
7.33 8.64 12 8.91 5.78 3.70 5.91 14 11 10
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
7.33 8.64 12 8.91 5.78 3.70 5.91 14 11 10
Common Stock
63 73 85 86 92 95 102 120 122 124
Retained Earnings
-39 -61 -61 -61 -81 -81 -81 -101 -112 -115
Accumulated Other Comprehensive Income / (Loss)
0.09 0.02 0.01 0.24 -0.12 0.58 0.56 1.00 1.00 0.87

Annual Metrics And Ratios for Gain Therapeutics

This table displays calculated financial ratios and metrics derived from Gain Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 11,879,743.00 11,883,368.00 12,910,342.00 26,525,068.00 36,097,536.00
DEI Adjusted Shares Outstanding
0.00 11,879,743.00 11,883,368.00 12,910,342.00 26,525,068.00 36,097,536.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -1.17 -1.48 -1.72 -0.77 -0.56
Growth Metrics
- - - - - -
Revenue Growth
0.00% 471.29% -15.08% -60.62% -100.00% 0.00%
EBITDA Growth
0.00% -289.30% -28.27% -26.90% 10.85% 3.46%
EBIT Growth
0.00% -288.68% -28.59% -26.91% 10.81% 3.40%
NOPAT Growth
0.00% -297.37% -28.58% -25.18% 8.55% 8.06%
Net Income Growth
0.00% -288.26% -26.64% -26.59% 8.34% 1.23%
EPS Growth
0.00% -3.01% -8.03% -15.54% 47.95% 31.46%
Operating Cash Flow Growth
0.00% -281.63% -18.81% -28.41% -0.04% 2.16%
Free Cash Flow Firm Growth
0.00% 0.00% -26.38% -29.51% -5.24% 9.50%
Invested Capital Growth
0.00% -142.24% -89.73% -40.48% 28.53% 28.22%
Revenue Q/Q Growth
0.00% 59.29% -33.49% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% -12.67% -9.33% -0.22% 6.92% -6.74%
EBIT Q/Q Growth
0.00% -12.68% -9.37% -0.25% 6.90% -6.75%
NOPAT Q/Q Growth
0.00% -13.02% -8.23% 0.69% 5.02% -6.46%
Net Income Q/Q Growth
0.00% -12.69% -9.01% -0.22% 4.47% -3.97%
EPS Q/Q Growth
0.00% 19.88% -16.54% 5.52% 19.09% -5.17%
Operating Cash Flow Q/Q Growth
0.00% -29.79% 1.62% -10.26% 10.46% -6.73%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 5.16% -5.83% 8.53% -10.89%
Invested Capital Q/Q Growth
0.00% 49.81% -8.27% 16.28% 1.43% 24.32%
Profitability Metrics
- - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin
-12,348.40% -8,414.61% -12,710.87% -40,954.88% 0.00% 0.00%
Operating Margin
-12,047.54% -8,379.80% -12,688.10% -40,328.26% 0.00% 0.00%
EBIT Margin
-12,381.61% -8,424.00% -12,756.67% -41,106.34% 0.00% 0.00%
Profit (Net Income) Margin
-12,387.67% -8,418.86% -12,555.13% -40,354.33% 0.00% 0.00%
Tax Burden Percent
100.15% 100.03% 100.53% 100.36% 102.70% 104.46%
Interest Burden Percent
99.90% 99.91% 97.90% 97.82% 98.23% 98.75%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-57.69% -67.73% -65.52% -141.57% -204.95% -155.66%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-37.23% -57.21% -56.66% -106.22% 0.00% 0.00%
Return on Assets (ROA)
-37.25% -57.18% -55.77% -104.28% 0.00% 0.00%
Return on Common Equity (ROCE)
-57.68% -67.73% -65.52% -141.57% -204.95% -155.66%
Return on Equity Simple (ROE_SIMPLE)
-57.69% -39.90% -93.17% -177.03% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.44 -9.68 -12 -16 -14 -13
NOPAT Margin
-8,433.28% -5,865.86% -8,881.67% -28,229.78% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-16.88% -19.61% -17.85% -35.49% -47.11% -46.50%
Return On Investment Capital (ROIC_SIMPLE)
- - - -118.49% -183.15% -69.06%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
4,325.08% 4,137.69% 6,808.94% 19,550.02% 0.00% 0.00%
R&D to Revenue
7,822.46% 4,342.11% 5,979.17% 20,878.24% 0.00% 0.00%
Operating Expenses to Revenue
12,147.54% 8,479.80% 12,788.10% 40,428.26% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-3.58 -14 -18 -23 -20 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.57 -14 -18 -23 -20 -19
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
6.45 1.85 1.97 3.35 7.81 6.26
Price to Tangible Book Value (P/TBV)
6.45 1.86 1.99 3.40 7.95 6.30
Price to Revenue (P/Rev)
1,384.99 390.97 265.47 763.90 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
1,150.74 171.65 112.19 469.83 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
0.12 0.02 0.03 0.05 0.06 0.02
Long-Term Debt to Equity
0.12 0.02 0.03 0.04 0.04 0.02
Financial Leverage
-1.09 -1.05 -1.07 -1.20 -1.31 -1.17
Leverage Ratio
1.55 1.18 1.17 1.36 1.54 1.35
Compound Leverage Factor
1.55 1.18 1.15 1.33 1.52 1.33
Debt to Total Capital
10.64% 1.96% 3.10% 4.32% 5.64% 2.11%
Short-Term Debt to Total Capital
0.33% 0.29% 0.56% 0.90% 1.42% 0.53%
Long-Term Debt to Total Capital
10.31% 1.66% 2.54% 3.42% 4.22% 1.58%
Preferred Equity to Total Capital
0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
89.36% 98.04% 96.90% 95.68% 94.36% 97.89%
Debt to EBITDA
-0.21 -0.05 -0.03 -0.03 -0.02 -0.02
Net Debt to EBITDA
1.90 2.61 1.21 0.72 0.49 1.05
Long-Term Debt to EBITDA
-0.20 -0.04 -0.03 -0.02 -0.02 -0.02
Debt to NOPAT
-0.30 -0.07 -0.05 -0.04 -0.03 -0.03
Net Debt to NOPAT
2.78 3.74 1.73 1.04 0.70 1.56
Long-Term Debt to NOPAT
-0.29 -0.06 -0.04 -0.03 -0.02 -0.02
Altman Z-Score
6.18 8.94 1.46 -1.90 -4.58 9.58
Noncontrolling Interest Sharing Ratio
0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - -
Current Ratio
4.25 14.78 5.11 3.59 2.97 6.63
Quick Ratio
3.55 14.45 4.88 3.39 2.66 6.22
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -8.87 -11 -15 -15 -14
Operating Cash Flow to CapEx
-15,558.61% -13,125.37% -12,351.21% -122,840.69% -83,909.78% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - -
Asset Turnover
0.00 0.01 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
3.38 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.97 2.43 1.12 0.41 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
108.03 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
108.03 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - -
Invested Capital
-0.57 -1.37 -2.60 -3.65 -2.61 -1.87
Invested Capital Turnover
-0.05 -0.17 -0.07 -0.02 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 -0.80 -1.23 -1.05 1.04 0.74
Enterprise Value (EV)
33 28 16 26 47 96
Market Capitalization
40 65 37 42 57 116
Book Value per Share
$2.31 $2.93 $1.59 $0.97 $0.28 $0.51
Tangible Book Value per Share
$2.31 $2.91 $1.57 $0.96 $0.27 $0.51
Total Capital
6.94 36 19 13 7.78 19
Total Debt
0.74 0.69 0.60 0.57 0.44 0.40
Total Long-Term Debt
0.72 0.59 0.50 0.45 0.33 0.30
Net Debt
-6.77 -36 -21 -16 -9.95 -20
Capital Expenditures (CapEx)
0.02 0.09 0.12 0.02 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.61 -1.61 -3.06 -3.85 -2.58 -1.85
Debt-free Net Working Capital (DFNWC)
6.90 35 17 13 7.80 19
Net Working Capital (NWC)
6.87 35 17 13 7.69 19
Net Nonoperating Expense (NNE)
1.14 4.21 5.15 6.69 6.17 7.06
Net Nonoperating Obligations (NNO)
-6.77 -36 -21 -16 -9.95 -20
Total Depreciation and Amortization (D&A)
0.01 0.02 0.06 0.08 0.08 0.09
Debt-free, Cash-free Net Working Capital to Revenue
-2,107.47% -974.19% -2,187.16% -6,971.63% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
23,875.98% 21,378.55% 12,186.44% 23,464.49% 0.00% 0.00%
Net Working Capital to Revenue
23,797.64% 21,315.62% 12,109.26% 23,249.20% 0.00% 0.00%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($1.37) ($1.48) ($1.71) ($0.89) ($0.61)
Adjusted Weighted Average Basic Shares Outstanding
0.00 10.17M 11.88M 13.01M 22.88M 32.97M
Adjusted Diluted Earnings per Share
$0.00 ($1.37) ($1.48) ($1.71) ($0.89) ($0.61)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 10.17M 11.88M 13.01M 22.88M 32.97M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 11.88M 11.88M 16.22M 27.79M 42.24M
Normalized Net Operating Profit after Tax (NOPAT)
-2.44 -9.68 -12 -16 -14 -13
Normalized NOPAT Margin
-8,433.28% -5,865.86% -8,881.67% -28,229.78% 0.00% 0.00%
Pre Tax Income Margin
-12,369.02% -8,416.43% -12,488.77% -40,210.67% 0.00% 0.00%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-13.16% -6.14% 0.00% 0.00% -1.38% -1.96%

Quarterly Metrics And Ratios for Gain Therapeutics

This table displays calculated financial ratios and metrics derived from Gain Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
16,219,709.00 18,051,979.00 25,535,460.00 26,525,068.00 27,786,952.00 29,557,640.00 35,948,606.00 36,097,536.00 42,241,947.00 42,654,038.00 43,643,619.00
DEI Adjusted Shares Outstanding
16,219,709.00 18,051,979.00 25,535,460.00 26,525,068.00 27,786,952.00 29,557,640.00 35,948,606.00 36,097,536.00 42,241,947.00 42,654,038.00 43,643,619.00
DEI Earnings Per Adjusted Shares Outstanding
-0.25 -0.45 -0.18 -0.14 -0.16 -0.20 -0.15 -0.13 -0.13 -0.11 -0.07
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
22.16% -5.59% 4.68% 31.26% -8.81% 30.68% -5.09% -37.30% -23.56% 19.03% 35.06%
EBIT Growth
22.06% -5.58% 4.64% 31.16% -8.77% 30.58% -5.09% -37.26% -23.46% 18.88% 34.97%
NOPAT Growth
16.29% -5.84% 8.72% 24.42% 0.19% 37.80% -7.33% -34.07% -22.52% 8.01% 33.07%
Net Income Growth
21.86% -5.92% 4.93% 20.23% -12.85% 28.66% -17.81% -20.42% -23.81% 19.51% 40.19%
EPS Growth
48.84% 32.26% 54.05% 72.41% 27.27% 54.76% 11.76% -37.50% 18.75% 42.11% 53.33%
Operating Cash Flow Growth
14.96% -14.64% -53.18% 38.97% -6.55% 11.42% 18.92% -33.69% -23.71% 8.22% 38.15%
Free Cash Flow Firm Growth
-7.57% -131.67% -230.95% -65.84% -40.86% -1.73% 27.13% -14.51% -20.10% 22.99% 3.56%
Invested Capital Growth
-14.07% -3.17% 39.29% 28.53% 18.46% 45.41% 6.51% 28.22% 24.59% 43.12% 46.67%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
14.67% -100.68% 44.45% 27.74% -35.07% -27.84% 15.78% 5.59% -21.56% 16.23% 32.46%
EBIT Q/Q Growth
14.66% -100.17% 44.32% 27.61% -34.83% -27.75% 15.71% 5.45% -21.27% 16.06% 32.44%
NOPAT Q/Q Growth
0.67% -86.92% 45.51% 25.29% -31.17% -16.48% 5.97% 6.68% -19.87% 12.55% 31.58%
Net Income Q/Q Growth
15.03% -102.86% 44.91% 15.99% -20.22% -28.23% 9.03% 14.13% -23.61% 16.64% 32.41%
EPS Q/Q Growth
24.14% -90.91% 59.52% 52.94% -100.00% -18.75% 21.05% 26.67% -18.18% 15.38% 36.36%
Operating Cash Flow Q/Q Growth
36.64% -60.50% -5.56% 43.14% -10.62% -33.43% 3.38% 6.25% -2.36% 1.01% 34.89%
Free Cash Flow Firm Q/Q Growth
-29.40% -112.24% 13.46% 30.22% -9.90% -53.28% 38.00% -9.65% -15.26% 1.71% 22.37%
Invested Capital Q/Q Growth
3.78% -32.88% 43.29% 1.43% -9.78% 11.04% 2.87% 24.32% -15.32% 32.90% 8.93%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.50% 100.01% 100.25% 115.47% 102.27% 102.49% 111.60% 101.57% 103.37% 102.28% 102.35%
Interest Burden Percent
97.19% 98.97% 97.70% 98.44% 99.10% 99.25% 98.38% 98.17% 98.31% 98.68% 98.66%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-177.83% -188.83% -263.14% -204.95% -290.21% -240.21% -261.72% -155.66% -214.69% -268.30% -223.94%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-177.83% -188.83% -263.14% -204.95% -290.21% -240.21% -261.72% -155.66% -214.69% -268.30% -223.94%
Return on Equity Simple (ROE_SIMPLE)
-244.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.06 -5.73 -3.12 -2.33 -3.06 -3.56 -3.35 -3.13 -3.75 -3.28 -2.24
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-6.26% -15.06% -11.74% -10.98% -14.15% -19.80% -19.40% -9.29% -15.01% -14.73% -9.25%
Return On Investment Capital (ROIC_SIMPLE)
-33.49% -46.68% -33.19% -29.98% -49.27% -85.90% -52.89% -16.48% -26.06% -28.16% -21.44%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-4.11 -8.23 -4.58 -3.32 -4.47 -5.71 -4.81 -4.55 -5.52 -4.63 -3.13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-4.09 -8.21 -4.56 -3.29 -4.45 -5.69 -4.79 -4.52 -5.50 -4.61 -3.11
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
7.08 1.96 5.10 7.81 9.18 14.39 10.77 6.26 5.85 7.67 7.44
Price to Tangible Book Value (P/TBV)
7.22 1.99 5.19 7.95 9.39 14.91 10.98 6.30 5.89 7.72 7.49
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.06 0.04 0.06 0.06 0.07 0.12 0.07 0.02 0.03 0.03 0.03
Long-Term Debt to Equity
0.05 0.03 0.04 0.04 0.05 0.09 0.05 0.02 0.02 0.02 0.02
Financial Leverage
-1.28 -1.40 -1.43 -1.31 -1.44 -1.47 -1.35 -1.17 -1.25 -1.27 -1.24
Leverage Ratio
1.51 1.64 1.75 1.54 1.82 1.88 1.71 1.35 1.53 1.69 1.51
Compound Leverage Factor
1.47 1.62 1.71 1.52 1.80 1.86 1.68 1.32 1.51 1.66 1.49
Debt to Total Capital
5.55% 3.96% 5.26% 5.64% 6.89% 10.89% 6.70% 2.11% 2.60% 2.95% 2.95%
Short-Term Debt to Total Capital
1.21% 0.91% 1.26% 1.42% 1.82% 3.04% 1.98% 0.53% 0.70% 1.06% 1.14%
Long-Term Debt to Total Capital
4.34% 3.06% 4.00% 4.22% 5.07% 7.84% 4.72% 1.58% 1.90% 1.89% 1.81%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
94.45% 96.04% 94.74% 94.36% 93.11% 89.11% 93.30% 97.89% 97.40% 97.05% 97.05%
Debt to EBITDA
-0.02 -0.02 -0.02 -0.02 -0.02 -0.03 -0.02 -0.02 -0.02 -0.02 -0.02
Net Debt to EBITDA
0.57 0.75 0.53 0.49 0.42 0.35 0.46 1.05 0.79 0.66 0.64
Long-Term Debt to EBITDA
-0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.01 -0.01 -0.01
Debt to NOPAT
-0.03 -0.03 -0.03 -0.03 -0.03 -0.04 -0.03 -0.03 -0.03 -0.03 -0.02
Net Debt to NOPAT
0.81 1.08 0.77 0.70 0.61 0.52 0.68 1.56 1.17 0.94 0.92
Long-Term Debt to NOPAT
-0.03 -0.02 -0.03 -0.02 -0.02 -0.03 -0.02 -0.02 -0.02 -0.02 -0.02
Altman Z-Score
0.14 -3.23 -1.21 0.03 -4.97 -7.77 -3.57 11.75 2.77 2.35 2.71
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.77 2.84 2.99 2.97 2.22 1.79 2.52 6.63 4.69 4.36 5.36
Quick Ratio
2.53 2.60 2.62 2.66 1.80 1.29 2.11 6.22 4.26 3.81 4.94
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-2.63 -5.58 -4.83 -3.37 -3.71 -5.68 -3.52 -3.86 -4.45 -4.38 -3.40
Operating Cash Flow to CapEx
0.00% 0.00% -607,620,500.00% -365,569.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-3.51 -4.67 -2.65 -2.61 -2.86 -2.55 -2.47 -1.87 -2.16 -1.45 -1.32
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-0.43 -0.14 1.71 1.04 0.65 2.12 0.17 0.74 0.70 1.10 1.15
Enterprise Value (EV)
49 6.66 34 47 44 47 55 96 66 74 64
Market Capitalization
61 23 45 57 53 53 64 116 82 87 76
Book Value per Share
$0.53 $0.65 $0.35 $0.28 $0.21 $0.13 $0.16 $0.51 $0.33 $0.26 $0.23
Tangible Book Value per Share
$0.52 $0.64 $0.34 $0.27 $0.20 $0.12 $0.16 $0.51 $0.33 $0.26 $0.23
Total Capital
9.15 12 9.40 7.78 6.21 4.15 6.33 19 14 12 10
Total Debt
0.51 0.49 0.49 0.44 0.43 0.45 0.42 0.40 0.37 0.34 0.31
Total Long-Term Debt
0.40 0.38 0.38 0.33 0.31 0.33 0.30 0.30 0.27 0.22 0.19
Net Debt
-12 -16 -12 -9.95 -8.64 -6.24 -8.38 -20 -16 -13 -11
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-3.69 -4.81 -2.78 -2.58 -2.83 -2.46 -2.34 -1.85 -2.10 -1.42 -1.25
Debt-free Net Working Capital (DFNWC)
8.97 12 9.26 7.80 6.24 4.24 6.47 19 14 12 10
Net Working Capital (NWC)
8.86 12 9.15 7.69 6.12 4.11 6.35 19 14 12 10
Net Nonoperating Expense (NNE)
0.95 2.42 1.36 1.44 1.47 2.25 1.93 1.41 1.86 1.40 0.92
Net Nonoperating Obligations (NNO)
-12 -16 -12 -9.95 -8.64 -6.24 -8.38 -20 -16 -13 -11
Total Depreciation and Amortization (D&A)
0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.02 0.03 0.02
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.22) ($0.42) ($0.17) ($0.08) ($0.16) ($0.19) ($0.15) ($0.11) ($0.13) ($0.11) ($0.07)
Adjusted Weighted Average Basic Shares Outstanding
17.98M 19.22M 26.53M 22.88M 28.69M 30.34M 35.00M 32.97M 42.23M 42.88M 43.77M
Adjusted Diluted Earnings per Share
($0.22) ($0.42) ($0.17) ($0.08) ($0.16) ($0.19) ($0.15) ($0.11) ($0.13) ($0.11) ($0.07)
Adjusted Weighted Average Diluted Shares Outstanding
17.98M 19.22M 26.53M 22.88M 28.69M 30.34M 35.00M 32.97M 42.23M 42.88M 43.77M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
18.05M 25.54M 26.53M 27.79M 29.56M 35.95M 36.10M 42.24M 42.65M 43.64M 44.53M
Normalized Net Operating Profit after Tax (NOPAT)
-3.06 -5.73 -3.12 -2.33 -3.06 -3.56 -3.35 -3.13 -3.75 -3.28 -2.24
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-1.33% 0.00% -1.31% -1.38% 0.00% 0.00% -2.04% -1.96% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Gain Therapeutics (NASDAQ: GANX) remains a pre-revenue biotechnology company with substantial ongoing cash burn. Revenue was $0 in each reported quarter, including Q2 2026, leaving the company dependent on cash reserves, equity financing and potential strategic funding to support its pipeline.

There were some sequential improvements in operating performance. Q2 2026 operating expenses declined to $4.7 million from $5.4 million in Q1 2026 and $5.1 million in Q2 2025. Research and development spending fell to $2.1 million from $2.8 million a year earlier, while the net loss narrowed to $4.7 million from $5.8 million in Q2 2025. However, SG&A expense increased year over year to $2.5 million, and the company remains far from profitability.

Cash flow continues to be the primary financial risk. Gain Therapeutics used $4.7 million in operating cash during Q2 2026, compared with $5.1 million in Q2 2025. The company ended the quarter with $13.1 million in cash, down from $16.5 million at the end of Q1 2026. Based solely on the latest quarterly operating burn and without additional financing, this cash balance would provide less than one year of funding, although actual runway will depend on spending changes and future capital raises.

The balance sheet is relatively lightly levered, with total debt of approximately $344,000 versus $13.1 million of cash. Total current assets of $15.0 million exceeded current liabilities of $3.4 million by a wide margin. Nevertheless, accumulated retained earnings were negative $111.6 million, reflecting the company’s long history of losses. Common stock issuance has also become an important source of liquidity, increasing the risk of dilution for existing shareholders.

  • Operating expenses are trending lower. Q2 2026 expenses fell approximately 13% sequentially and 8% year over year, led by a substantial reduction in research and development spending.
  • Net losses have improved from the prior-year quarter. The Q2 2026 net loss of $4.7 million was better than the $5.8 million loss recorded in Q2 2025 and the $5.6 million loss in Q1 2026.
  • The company maintains a low-debt balance sheet. Cash and equivalents of $13.1 million were far greater than total short- and long-term debt of approximately $344,000.
  • Liquidity remains supported by a strong current ratio. Current assets of $15.0 million compared with current liabilities of $3.4 million indicate substantial short-term asset coverage.
  • Interest and investment income provides a modest offset. Q2 2026 interest and investment income was $61,000, but this amount is small relative to the company’s quarterly operating expenses.
  • Noncash adjustments continue to reduce the gap between accounting losses and operating cash burn. Q2 2026 included $666,000 of noncash adjustments, making operating cash usage somewhat lower than the reported net loss.
  • Gain Therapeutics has not generated revenue. Revenue and gross profit were both $0 in the reported quarters, so the company has no recurring commercial sales to fund operations.
  • Operating cash flow remains consistently negative. The company used $4.7 million in operating cash in Q2 2026 and has reported recurring quarterly operating cash outflows throughout the provided period.
  • Cash reserves declined sharply during Q2. Cash fell by $3.5 million from Q1 2026 to Q2 2026 even after the company raised approximately $1.4 million through common equity issuance.
  • Future financing is likely to create dilution risk. Weighted-average basic shares outstanding rose to 42.9 million in Q2 2026 from 30.3 million in Q2 2025, while recent quarters show repeated common-stock issuances to help fund operations.
11/20/26 01:10 AM ETAI Generated. May Contain Errors.

Gain Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Gain Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Gain Therapeutics' net income appears to be on a downward trend, with a most recent value of -$20.16 million in 2025, falling from -$3.58 million in 2020. The previous period was -$20.41 million in 2024. Check out Gain Therapeutics' forecast to explore projected trends and price targets.

Gain Therapeutics' total operating income in 2025 was -$18.71 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $18.71 million

Over the last 5 years, Gain Therapeutics' total revenue changed from $28.88 thousand in 2020 to $0.00 in 2025, a change of -100.0%.

In the past 12 quarters, Gain Therapeutics' cash and equivalents has ranged from $4.27 million in Q3 2023 to $16.94 million in Q2 2024, and is currently $11.70 million as of their latest financial filing in Q3 2026.

Gain Therapeutics had total debt of $400.95 thousand at the end of 2025, a 8.6% decrease from 2024, and a 45.7% decrease since 2020.

Over the last 5 years, Gain Therapeutics' book value per share changed from 2.31 in 2020 to 0.51 in 2025, a change of -77.8%.



Financial statements for NASDAQ:GANX last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners